206 related articles for article (PubMed ID: 27255419)
21. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
22. Regulatory role of hexosamine biosynthetic pathway on hepatic cancer stem cell marker CD133 under low glucose conditions.
Lin SH; Liu T; Ming X; Tang Z; Fu L; Schmitt-Kopplin P; Kanawati B; Guan XY; Cai Z
Sci Rep; 2016 Feb; 6():21184. PubMed ID: 26878908
[TBL] [Abstract][Full Text] [Related]
23. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
24. G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133⁺ cancer stem-like cells in hepatocellular carcinoma.
Yan M; Li H; Zhu M; Zhao F; Zhang L; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
PLoS One; 2013; 8(4):e61056. PubMed ID: 23593389
[TBL] [Abstract][Full Text] [Related]
25. Peroxiredoxin II Is Essential for Maintaining Stemness by Redox Regulation in Liver Cancer Cells.
Kwon T; Bak Y; Park YH; Jang GB; Nam JS; Yoo JE; Park YN; Bak IS; Kim JM; Yoon DY; Yu DY
Stem Cells; 2016 May; 34(5):1188-97. PubMed ID: 26866938
[TBL] [Abstract][Full Text] [Related]
26. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J
Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of Bmi‑1 promotes epithelial‑mesenchymal transition in CD133+Hep G2 cells.
Zhang Z; Wang Q; Bu X; Zhang C; Chen H; Sha W; Liu W
Mol Med Rep; 2017 Nov; 16(5):6156-6161. PubMed ID: 28849237
[TBL] [Abstract][Full Text] [Related]
28. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
29. MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133
Xu Y; Lai Y; Weng H; Tan L; Li Y; Chen G; Luo X; Ye Y
Aging (Albany NY); 2019 May; 11(9):2551-2564. PubMed ID: 31056532
[TBL] [Abstract][Full Text] [Related]
30. Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133
Song Y; Park IS; Kim J; Seo HR
Chem Biol Interact; 2019 Aug; 309():108713. PubMed ID: 31226288
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta.
You H; Ding W; Rountree CB
Hepatology; 2010 May; 51(5):1635-44. PubMed ID: 20196115
[TBL] [Abstract][Full Text] [Related]
32. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
[TBL] [Abstract][Full Text] [Related]
33. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma.
Tong M; Fung TM; Luk ST; Ng KY; Lee TK; Lin CH; Yam JW; Chan KW; Ng F; Zheng BJ; Yuan YF; Xie D; Lo CM; Man K; Guan XY; Ma S
Stem Cell Reports; 2015 Jul; 5(1):45-59. PubMed ID: 26095609
[TBL] [Abstract][Full Text] [Related]
34. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma.
Liu WT; Jing YY; Yu GF; Han ZP; Yu DD; Fan QM; Ye F; Li R; Gao L; Zhao QD; Wu MC; Wei LX
Cancer Lett; 2015 Mar; 358(2):136-143. PubMed ID: 25511737
[TBL] [Abstract][Full Text] [Related]
35. Biology and clinical implications of CD133(+) liver cancer stem cells.
Ma S
Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
[TBL] [Abstract][Full Text] [Related]
36. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo.
Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L
Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787
[TBL] [Abstract][Full Text] [Related]
37. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment.
Song YJ; Zhang SS; Guo XL; Sun K; Han ZP; Li R; Zhao QD; Deng WJ; Xie XQ; Zhang JW; Wu MC; Wei LX
Cancer Lett; 2013 Oct; 339(1):70-81. PubMed ID: 23879969
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
[TBL] [Abstract][Full Text] [Related]
39. The role of CD133 in hepatocellular carcinoma.
Liu F; Qian Y
Cancer Biol Ther; 2021 Apr; 22(4):291-300. PubMed ID: 33899676
[TBL] [Abstract][Full Text] [Related]
40. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
